Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

Part of paid clinical trials in Seattle, Washington.

Sponsor
Presage Biosciences
Study ID
NCT01831505
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Many cancer patients are prescribed drugs to which their cancer is already resistant - and thus suffer toxicity with no potential for benefit. Previous attempts to assess chemoresistance or sensitivity in vitro have failed. This is a feasibility study in human patients with newly diagnosed or recurrent lymphoma to determine how human cancerous lymph nodes in situ respond to standard of care therapeutics precisely microinjected with the CIVO(tm) microdosing system.

Key Dates

Start date
Nov 30, 2012
Status verified
Feb 2017
Primary completion
Jul 31, 2013
Completion
Jul 31, 2013

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Multiple drug microinjection
    Multiple drug microinjection with locally injected rituximab, vincristine, doxorubicin, bendamustine, prednisolone, or a combination of them

Primary Outcome Measure

Evaluation of the response to locally injected drugs [ Time Frame: 1-3 days post injection after injection ]

Locations (1)

FacilityCityStateZIPSite coordinators
Seattle Cancer Care AllianceSeattleWashington98109-

Find similar trials in Seattle, WA

By research site
Seattle Cancer Care Alliance· Seattle, WA

Related Studies